Temporal outcomes and biomarkers of rituximab treatment response in pemphigus: Validation of a historical control dataset. (PubMed, JID Innov) - Oct 11, 2026 - "A desmoglein 3 ELISA index value ≤ 130 RU/ml and > 90.7% titer reduction between months 3 and 9 demonstrated 90% specificity and 88% sensitivity for future achievement of complete remission off oral immunosuppressive therapy, with negative predictive values of 85% and 92%, respectively, suggesting that low and/or rapid large drops in autoantibody titers after rituximab may predict an absence of disease activity. These data describe the temporal outcomes of rituximab therapy in pemphigus vulgaris and validate the historical control dataset for future comparative effectiveness research and biomarker-driven management."
Biomarker • Journal • Dermatology • Immunology • Pemphigus Vulgaris
|
|
Aimee S Payne; Chuda Rujitharanawong; Sasima Tongsai
|